Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

  • STATUS
    Recruiting
  • participants needed
    222
  • sponsor
    Hangzhou ACEA Pharmaceutical Research Co.,Ltd.
Updated on 8 November 2020
cancer
measurable disease
metastasis
erlotinib
EGFR
brain metastases
alopecia
gefitinib
recurrent non-small cell lung cancer

Summary

The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the study drug's efficacy and safety.

Description

The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the study drug's efficacy and safety with overall objective tumor response rate (ORR) as the primary efficacy evaluation indicator, and further evaluate subjects' duration of response (DOR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS) and quality of life (QoL). Safety indicators of subjects are further evaluated through adverse events, vital signs and clinical laboratory parameters.

Details
Treatment AC0010
Clinical Study IdentifierNCT03300115
SponsorHangzhou ACEA Pharmaceutical Research Co.,Ltd.
Last Modified on8 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have Metastatic Non Small Cell Lung Cancer?
Aged 18-75 years (including 18 and 75 years old)
Histologically or cytologically confirmed metastatic or unresectable locally advanced, recurrent non-small cell lung cancer which cannot receive radical surgery and radiotherapy
The patient has at least one radio graphically (CT, MRI)measurable lesion according to the RECIST criteria for solid tumor response; long-diameter of tumor scanned by CT&MRI 10mm, or short-diameter of metastatic cervical lymph nodes15mm. With no radiotherapy and biopsy
Patients without CNS metastases or asymptomatic patients with brain metastases. The number of CNS metastases focus2, maximum diameter <10mm
Document prove EGFR mutation before treatment of EGFR TKI, or show clinical benefit after treatment of EGFR TKI (PR, CR evaluation according to RECIST or more than half-year SD duration); tumor tissue proved to be EGFR T790M positive mutation by center lab after last treatment
Patients need to undergo biopsy of primary or metastatic tumor tissue and provide pathological sections to site's central lab; otherwise, the patients need to undergo biopsy of primary or metastatic tumor tissue in the screening period and provide pathological sections to the site's central laboratory
Patients who have previously received first-generation EGFR-TKI (erlotinib, gefitinib, ectectin) treatment and developed resistance and are only allowed to have received one chemotherapy regimen (maintenance treatment with the same drug is allowed; but maintenance treatment with a different drug is not allowed), or are positive for primary T790M mutation but have not received treatment or have only received first-line treatment
The patient must have good organ function, including meeting the laboratory test requirements at screening
Patients must recover to Grade 1 (CTCAE v4.03)toxicity from the previous treatment (patients with any grade of hair loss are allowed to enter the study)
ECOG score: 0-1 points. No deterioration in the last 2 weeks
Expected survival time:> 12 weeks
Patients who can cooperate with the observation of adverse events and efficacy
Patients or their legal representatives have signed a written informed consent form

Exclusion Criteria

Acute hepatitis C, chronic hepatitis C and active hepatitis B (positive HBsAg; HBcAb or HBeAb positive and HBV DNA positive)
HIV antibody positive, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation
A past history of interstitial lung disease and radiation pneumonia
Clinically significant abnormalities of resting ECG in rhythm, conduction and morphology, such as complete left bundle branch block, Grade II and above heart block, PR interval> 250 ms, or myocardial infarction within the past 6 months; there are risk factors leading to prolongation of QTc interval or increasing arrhythmias, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or medical history of sudden death at an age of < 40 years among the patient's first-degree relatives, and 12-lead ECG QT interval correction Fridericia method (QTcF interval)> 450 ms for male, >470ms for female
The investigator judges based on safety concerns or clinical study process that the patient had any other condition that is prohibited for participation in the clinical study, such as severe infection/inflammation, intestinal obstruction, inability to swallow medication, social/psychological problems, etc
With clinically significant electrolyte abnormalities in laboratory tests
\. In addition to NSCLC, patients who have been diagnosed with another and/or
treatment-requiring malignant disease in recent 5 years (this exclusion
criterion does not include the following circumstances: completely resected
basal cell and squamous cell skin cancer, inert malignant tumor currently
requiring no treatment, and any type of completely resected carcinoma in
situ)
Patients who have used high-dose glucocorticoids or other immunosuppressive
agents within 1 month prior to screening
\. Interval time between previous EGFR TKI treatment and AC0010 <8 days or 5
half-time, subject to the long time; Interval time between major surgery
radiotherapy and AC0010 <4 weeks; Patients who are using any drug known to
prolong QT interval or known potent CYP3A4 enzyme inducer or inhibitor within
weeks before the first dose
Patients who have used high-dose glucocorticoids or other immunosuppressive
agents within 1 month prior to screening
\. Patients who have previously administered third-generation EGFR-TKI drugs
(e.g.,AZD9291, Avitinib, CO-1686, HM61713, etc.)
\. Patients who have been registered and received the study treatment or
withdrawn from the study cannot be enrolled
\. Pregnant or lactating women
\. Women with childbearing potential are defined as all women who are
physiologically able to have a pregnancy, unless they are using an efficient
contraceptive method during treatment and within 7 days after discontinuation
of treatment
\. Patients who are considered by the investigator as inappropriate to
participate in the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet